BRCA1 and cancer: However, the recent introduction of poly ADP ribose polymerase (PARP) inhibitors to treat patients with BRCA1/2 variants resulted in more expansion of the testing guidelines to include all patients who may potentially benefit from certain anti-cancer therapy used in the setting of BRCA1/2 variants.